Strategic Focus Privately held, clinical-stage immunotherapy company with two global subsidiaries (Paris research arm and Houston development arm) pursuing first-in-class cancer therapies, signaling readiness for strategic partnerships, joint development, or licensing opportunities to accelerate clinical programs.

HLA-G CAR-T Opportunity Lead program centers on HLA-G targeted CAR-T therapies for solid tumors, evidenced by recent ASCO 2025 data presentation and multiple translational development awards, presenting a clear entry point for oncology CROs, manufacturing partners, and cytotherapy collaboration.

Financing & Resources Raised over 60–68 million in private funding with ongoing growth potential, indicating a sponsor seeking collaborations to de-risk and accelerate trials, including potential co-development, equity partnerships, or milestone-driven alliances.

Strategic Collaborations Past and ongoing collaborations with MD Anderson and CTMC for scalable CAR-T process development highlight openness to ecosystem partnerships for manufacturing, supply chain, and translational platforms.

Market Readiness Recent ASCO participation and awards signal market validation and ongoing visibility in oncology circles, presenting opportunities for early access programs, advisory roles, and long-term commercial planning with biotech and pharma buyers.